
-
Thousands of carpets sunbathe at Turkish resort
-
'I didn't feel safe': Banned Canada coach explains move to New Zealand
-
Norwegian cousins battle over oil, climate policy
-
Zverev makes winning Toronto return after a month off court
-
Thailand accuses Cambodia of 'flagrant violation' of truce
-
'Marathon at F1 speed': China bids to lap US in AI leadership
-
Stablecoins inspire hope, and hype, in Hong Kong
-
Markets mixed as China-US talks end, eyes on tech earnings
-
Huge quake off Russia sparks Pacific tsunami warnings
-
Top seed Gauff outlasts Collins to advance at Montreal
-
Ukraine says Russian strike on training camp kills 3 soldiers
-
Trump's MAGA base defies conservative pro-Israel doctrine
-
US Fed set to hold firm against Trump pressure
-
Five products to be hit by Trump's incoming tariffs
-
US second quarter GDP growth to reflect tariff turbulence
-
US, India to launch powerful Earth-monitoring satellite
-
Australia to ban under-16s from YouTube
-
England and India fight fatigue as gripping Test series goes to the wire
-
American Eagle 'jeans' campaign that stars Sydney Sweeney under fire
-
Portugal battles to contain wildfires
-
FIFA World Cup draw in Vegas on December 5: reports
-
Japanese qualifier Ito ousts seventh seed Paolini in Montreal
-
New Athletic captain Williams 'lucky' to represent migrants in Spain
-
Musetti, Rune set winning pace for ATP seeds in Toronto
-
Venus Williams gets US Open mixed doubles wild card spot
-
Global stocks mixed as market focus shifts to earnings deluge
-
Tens of thousands of Catholics head to Vatican's Jubilee of Youth
-
Trump says fell out with Epstein because he was taking Mar-a-Lago spa staff
-
Russia strikes kill 25 in Ukraine as Trump shortens Moscow deadline
-
US pushes to revoke scientific ruling that underpins climate regulations
-
US says Trump has 'final call' on China trade truce
-
Goalkeeper Trafford returns to Man City from Burnley
-
Boeing reports smaller loss as CEO sees progress in turnaround
-
Qatar, Saudi, Egypt join call for Hamas to disarm, give up Gaza rule
-
Trump opens Scottish golf course and vows 'peaceful world'
-
Aubameyang close to Marseille return: club
-
Gucci owner Kering posts 46% profit slump before new CEO arrives
-
Cambodia-Thailand truce broadly holds despite shaky start
-
P&G estimates $1 bn tariff hit, plans some US price hikes
-
Wiebes claims Tour de France stage as Vos holds lead
-
Mbeumo looks forward to Fernandes link-up at Man Utd
-
Displaced Cambodians return home after Thailand truce
-
Stock market attention shifts from trade deals to company results
-
Tens of thousands in Rome for Vatican's Jubilee of Youth
-
Pogacar to skip Vuelta after Tour de France triumph
-
New York mass shooter blamed NFL for his brain injuries
-
Impressive Scandinavia delivers O'Brien Goodwood Cup 1-2
-
US to overturn foundational climate ruling on Tuesday
-
Russia strikes kill 25 in Ukraine as Kremlin notes new Trump deadline
-
Boeing reports smaller loss, sees more 'stability' in operations
RBGPF | -4.75% | 74.03 | $ | |
CMSC | 0.49% | 22.61 | $ | |
SCS | -3.24% | 10.51 | $ | |
SCU | 0% | 12.72 | $ | |
VOD | -0.45% | 11.11 | $ | |
RYCEF | 2.59% | 13.5 | $ | |
NGG | 0.28% | 70.52 | $ | |
RELX | 0.29% | 51.92 | $ | |
RIO | 0.13% | 62.27 | $ | |
BP | 0.88% | 32.96 | $ | |
CMSD | 0.95% | 23.12 | $ | |
JRI | 0.23% | 13.06 | $ | |
BCE | -0.72% | 23.66 | $ | |
BTI | 1.88% | 52.77 | $ | |
GSK | 0.58% | 37.67 | $ | |
BCC | -0.7% | 86.14 | $ | |
AZN | 2.91% | 73.98 | $ |

New hope for patients with less common breast cancer
A new treatment nearly halves the risk of disease progression or death from a less common form of breast cancer that hasn't seen major drug advances in over a decade, researchers reported Monday.
Results from the study, presented at the annual meeting of the American Society for Clinical Oncology, are expected to be submitted to regulators and could soon establish a new first-line therapy for people with HER2-positive metastatic breast cancer -- the advanced stage of a form that comprises 15–20 percent of all breast cancer cases.
HER2-positive cancers are fueled by an overactive HER2 gene, which makes too much of a protein called human epidermal growth factor receptor 2 that helps cancer cells grow and spread.
Patients with HER2-positive breast cancer that has spread to other parts of the body live around five years.
"Seeing such a striking improvement was really impressive to us -- we were taking a standard and almost doubling how long patients could have their cancer controlled for," oncologist Sara Tolaney, chief of the breast oncology division at Dana-Farber Cancer Institute, told AFP.
The current standard of care, known as THP, combines chemotherapy with two antibodies that block growth signals from the HER2 protein. The new approach uses a drug called trastuzumab deruxtecan (T-DXd), an antibody attached to a chemotherapy drug.
- 'Smart bomb' -
This "smart bomb" strategy allows the drug to target cancer cells directly. "You can bind to the cancer cell and dump all that chemo right into the cancer cells," explained Tolaney.
"Some people call them smart bombs because they're delivering chemo in a targeted fashion -- which is how I think we're able to really increase efficacy so much."
Common side effects included nausea, diarrhea and a low white blood cell count, with a less common effect involving lung scarring.
T-DXd is already approved as a "second-line" option -- used when first-line treatments stop working. But in the new trial, it was given earlier, paired with another antibody, pertuzumab.
In a global trial led by Tolaney, just under 400 patients were randomly assigned to receive T-DXd in combination with pertuzumab, thought to enhance its effects.
A similar number received the standard THP regimen. A third group, who received T-DXd without pertuzumab, was also enrolled -- but those results haven't yet been reported.
- 44 percent risk reduction -
At a follow-up of 2.5 years, the T-DXd and pertuzumab combination reduced the risk of disease progression or death by 44 percent compared to standard care.
Fifteen percent of patients in the T-DXd group saw their cancer disappear entirely, compared to 8.5 percent in the THP group.
Because this was an interim analysis, the median progression-free survival -- meaning the point at which half the patients had seen their cancer return or worsen -- was 40.7 months with the new treatment, compared to 26.9 months with the standard, and could rise further as more data come in.
Tolaney said the results would be submitted to regulators around the world, including the US Food and Drug Administration, and that future work would focus on optimizing how long patients remain on the treatment, particularly those showing complete remission.
"This represents a new first-line standard treatment option for HER2-positive metastatic breast cancer," said Dr. Rebecca Dent, a breast cancer specialist at the National Cancer Center Singapore who was not involved in the study
W.Nelson--AT